Companies/US/VCEL

VERICEL CORPORATION

Income flow

Annual
VCEL 10-K Income StatementPeriod 2025-12-31Source 10-K
MACIImplants And Kits$146MImplants$110MEpicel$19MBiopsy Kits$2MRevenue$276M+17% Y/YGross profit$206M+20% Y/YCost of revenue$71MOperating profit$11M+144% Y/YOperating expenses$195MNet profit$17M+59% Y/YTax$859,000SG&A$167MR&D & other$28M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$454M
  • MACIImplants And Kits$240M52.7%
  • Implants$180M39.7%
  • Epicel$32M7.1%
  • Biopsy Kits$3M0.6%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).51.2MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).50.6M
Stock splits
  1. 1:202013-10-16

Valuation

Trailing PE 112.5 (2025-12-31)PE trend

Fiscal PE2

PeriodEPSClosePE
2025-12-310.3236.01112.5
2024-12-310.254.91274.6

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.